Introduction
The tumour suppressor protein p53 mediates cell cycle arrest and/or apoptosis in response to a wide variety of cellular`stress' signals (Ko and Prives, 1996) . Several of these, notably oncogene activation (Serrano et al., 1997) , loss of cell-cycle regulators (Pan and Griep, 1994) and proliferative senescence (Bond et al., 1996) , can arise during tumorigenesis, hence it is not surprising that loss of p53 function is a common feature of human cancers (Greenblatt et al., 1994) . Most achieve this by direct mutation of the p53 gene. However an important sub-set, including sarcomas (Oliner et al., 1992) , thyroid (Blaydes et al., 1997) and some breast (Marchetti et al., 1995) cancers, appear to use a more indirect mechanism involving inappropriate expression of a functional inhibitor, mdm2 (Momand et al., 1992) , which binds to the transactivation domain of p53 (Oliner et al., 1993; Chen et al., 1993; Picksley et al., 1994; Kussie et al., 1996) . Not surprisingly, this interaction has aroused great interest as an ideal potential target for novel cancer therapies (BoÈ ttger et al., 1996) and indeed there is experimental evidence that its interruption can restore p53 function and arrest or kill cancer cells (Blaydes et al., 1997) . However, therapeutic speci®city may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality (Jones et al., 1995; Oca-Luna et al., 1995) , but, as highlighted in a recent review (Piette et al., 1997) , the situation in adult cells is still unclear.
Here we have investigated this question by microinjection of normal human ®broblasts with an antibody to the p53-binding domain of mdm2. The results indicate that normal adult cell proliferation may also be dependent on negative regulation of p53 by mdm2, a ®nding which raises a note of caution for mdm2-directed cancer therapies.
Results and discussion
As a model to investigate the role of mdm2 in normal proliferating cells, we examined the eect of disrupting mdm2-p53 complex formation on p53-dependent transcription and cell-cycle arrest in a widely-used human diploid ®broblast cell strain, HCA2 (Noda et al., 1994) . This was achieved by micro-injection of an anti-mdm2 antibody (3G5), an approach which we have already shown to be eective in a transformed rodent thyroid epithelial cell line (Blaydes et al., 1997) . The epitope recognised by 3G5 was originally mapped between amino acids 59 and 89 in the p53-binding domain of mdm2 (Chen et al., 1993) and more recently its core sequence has been localized to the p53 binding pocket on mdm2. Consistent with this, 3G5 has been shown to block p53-mdm2 interaction in vitro (Bottger et al., 1997a) .
We ®rst made use of an HCA2 subclone (HCA2-LacZ21) previously derived and extensively characterized in our laboratory (Bond et al., 1996) , which contains a stably-integrated p53-dependent reporter construct, pRGCDfos-lacZ (Frebourg et al., 1992) . HCA2-LacZ21 cells were injected with either 3G5, or control immunoglobulin (IgG), and expression of the reporter gene, bacterial b-galactosidase, was determined by histochemistry 24 h post-injection ( Figure  1 ). 3G5 induced a dramatic increase in p53-dependent transcription of the reporter gene, the proportion of positive cells (means of two experiments) increasing from 2.2% in IgG-injected controls to 76% in cells receiving 3G5.
To con®rm that this eect on p53-dependent transcription was not speci®c to the HCA2-LacZ21 reporter model, we next examined the eect of 3G5 micro-injection on the expression of an endogenous p53-responsive gene, p21
WAF-1 (El-Deiry et al., 1993) in the parental HCA2 cell line. Whilst p21 WAF-1 protein expression was only present in a minority of noninjected or IgG-injected cells, and in most of these at barely detectable levels (consistent with our previous observations on HCA2 cells at this passage level), both the percentage of positive cells and particularly the intensity of nuclear p21
WAF-1 immuno¯uorescence increased dramatically following 3G5-injection ( Figure 2) .
We next examined the ability of 3G5 to induce cell cycle arrest in HCA2 cells. 24 h post-injection, cells were re-fed with medium containing bromodeoxyuridine (BrdU) and incubated for a further 24 h to label nuclei undergoing DNA synthesis. 3G5 micro-injection reduced the BrdU labelling index to 3.5% (mean of three experiments), compared to a mean of 48% in control IgG injected cells (Figure 3 ). This induction of growth arrest was also associated with a distinctivē attening of the cells, comparable to that seen during p53-dependent senescence (Bond et al., 1996) .
As it is known that mdm2 has a number of potential cell cycle regulatory activities other than p53-binding (Dubs-Poterszman et al., 1995), we then asked whether this growth arrest induced by 3G5 was p53-dependent, by co-injecting HCA2 cells with both 3G5 and the antip53-antibody PAb1801 (Figure 3 ), micro-injection of which has been previously shown to inhibit p53-dependent transcription (AbarzuÂ a et al., 1995).
PAb1801 completely blocked 3G5-induced growth arrest, injected cells having a mean BrdU labelling index of 83%, clearly demonstrating that the cell cycle arrest induced by 3G5-micro-injection is p53-dependent. Indeed, the BrdU-labelling index in these cells exceeded that in control IgG-injected cells, indicating that even in the presence of functional mdm2, proliferation is being partially inhibited by p53.
The direct conclusion which can be drawn from these results is that the presence of functional mdm2 protein is an absolute requirement for the continued proliferation of normal human diploid ®broblasts in standard culture conditions, and that interruption of mdm2 function by anti-mdm2 antibody 3G5 leads to a p53-dependent growth arrest.
Assuming that the eect of 3G5 is the direct result of its preventing the formation of complexes between mdm2 and transcriptionally-active p53 (as opposed to other potential protein partners; Dubs-Poterszman et al., 1995; Martin et al., 1995; Xiao, 1995) , this leads to the important implication that in proliferating normal human cells, the constitutive level of activation of the p53`pathway' is sucient to induce growth arrest if p53 function is not eectively antagonized by mdm2.
One possible explanation for this constitutive activation of wild-type p53, in the absence of any obvious cellular`stress' signals, may be that it is a physiological response to growth factor stimulation, either direct or as a secondary consequence of the resulting proliferation. This would be consistent with the many reports of change in p53 content or conformation following growth factor stimulation (Milner, 1995) .
An alternative source of p53 activating signals, which is particularly relevant given the use here of normal cells as opposed to cell lines, is not the proliferative state per se, but rather the proliferative history of the cell. We have previously shown that the arrest of ®broblast proliferation at senescence requires wild-type p53 (Bond et al., 1994) and is accompanied by a dramatic increase in p53-driven transcriptional activity (Bond et al., 1996) . It is possible that the process of cellular ageing begins to activate p53 well before cells reach the end of their normal proliferative lifespan, and that the mdm2 feedback loop plays an important role in preventing the onset of premature senescence.
Irrespective of the underlying mechanism, however, demonstration of the requirement of mdm2 function for proliferation in cells which are the equivalent of normal adult ®broblasts is in itself an important extension of transgenic mouse data (Jones et al., 1995; Oca-Luna et al., 1995) , which demonstrated the need for mdm2 to prevent p53-mediated lethality during embryonic development but were uninformative regarding its importance post-natally. Furthermore, the data raise the possibility that inhibition of mdm2 expression (overriding its induction by p53) may be an important additional mechanism used by normal cells for modulating the level of free active p53. (We already have some evidence that, at least in cell lines expressing wt p53, the response to UV irradiation involves transient down-regulation of mdm2 expression (Blaydes et al., 1997).) Our ®ndings are entirely consistent with recent evidence that, in addition to inhibiting the transactivation function of p53, mdm2 also promotes degradation of the protein (Kubbutat et al., 1997; Haupt et al., 1997) . Indeed this mechanism would predict that inhibition of p53/mdm2 interaction, such as achieved here by 3G5, would lead not only to increased activity, but also to increased cellular content of p53. Although not examined here, such an accumulation of p53 was readily detectable in similar experiments performed on murine cell lines (BoÈ ttger et al., 1997b) .
These ®ndings have major potential implications for the use of novel therapies targetting mdm2. Peptides based on the mdm2 binding site of p53 have recently been shown to be capable of eciently blocking mdm2-p53 interaction in vitro (BoÈ ttger et al., 1996 (BoÈ ttger et al., , 1997b (analogous to the eect of 3G5 antibody). This raises hopes that these (or, more usefully, peptidomimetic drugs) could be used to reactivate wild-type p53 in those tumour types where the protein is not mutated but is critically inhibited by mdm2. These include the obvious situation in which the mdm2 gene is ampli®ed as a primary molecular event, as seen notably in sarcomas (Oliner et al., 1992) . There is increasing evidence however that in other tumour types, including thyroid follicular and probably many breast cancers, wild-type p53 is tolerated through a more subtle mdm2-dependent mechanism (Blaydes et al., 1997, Blaydes and Wynford-Thomas 1998) .
Until now, the essential assumption underlying the use of agents targetting mdm2 is that the release of biologically-active wild-type p53 capable of causing arrest and/or apoptosis will only occur in the cancer cells. Clearly our data call into question this speci®city, and in the worst case scenario raise the possibility that such therapies would lead to widespread p53-induced apoptosis in critical stem cell populations, such as gut, which appear to have a predeliction for undergoing apoptosis rather than growth arrest (Midgley et al., 1995) . There are however several reasons for taking a more optimistic view. First, the p53 pathway may only be active in non-stem cell populations, such as the ®broblasts studied here, which are not normally proliferating in vivo, and in which therefore release from inhibition by mdm2 is likely to be innocuous. Second, even if active p53 is released in stem cells, the eects may be more limited than those seen in response to DNA damaging agents, since DNA damage activates many other potential mechanisms of permanent growth arrest or apoptosis. The side-eects of p53/mdm2 targetted therapy may for example be limited to a temporary growth arrest of stem cells. Clearly, these issues will only be resolved by examining the eects of antagonising mdm2 function in a wide range of normal tissues in physiological conditions. The important message from the present study is that eects on normal cells must at least be anticipated in the design of future therapeutic strategies based on the mdm2/p53 interaction.
Materials and methods
Cell culture and micro-injection HCA2 and HCA2-LacZ21 cells were cultured in Dulbecco's modi®ed Eagle medium (Gibco ± BRL) supplemented with 10% foetal calf serum (FCS) (Gibco ± BRL) and were used 30 ± 39 population doublings (pd) subsequent to the establishment of the parental HCA2 strain (maximum lifespan was approximately 65 pd). Cells were microinjected with an Eppendorf microinjection system (Microinjector 5242, Micromanipulator 5170; Carl Zeiss, Oberkochen), mounted on an Axiovert 35 M microscope with heated stage. Puri®ed mouse monoclonal antibodies PAb1801 (Oncogene Science) and 3G5 (puri®ed using protein A-sepharose from hybridoma supernatant kindly supplied by Dr AJ Levine), were each injected at a ®nal concentration of 2 mg/ml in phosphate buered saline pH 7.4 (PBS). To facilitate subsequent immunodetection of microinjected cells, the concentration of mouse immunglobulins injected was brought up to 5 mg/ml with puri®ed mouse IgG (Sigma), which was also used in control injections. Likewise, a further 5 mg/ml puri®ed rabbit IgG (Sigma) was co-injected when BrdU incorporation was to be determined. Following injection, cells were refed and analysis commenced 24 h later.
Analysis of injected cells
b-galactosidase expression was assessed by X-gal histochemistry and injected cells were identi®ed by immunocytochemical detection of injected mouse immunoglobulins using peroxidase-conjugated goat anti-mouse IgG (DAKO) as described previously (Bond et al., 1996) .
For the analysis of p21 WAF1 expression, cells were ®xed in 4% paraformaldehyde in PBS for 10 min, incubated for 10 min in 100 mM glycine/PBS, 10 min in 0.2% Triton X100/ PBS and 30 min in 10% FCS/PBS. This was followed by a 1 h incubation with a rabbit polyclonal anti-p21 WAF1 antibody (Santa Cruz) diluted 1 : 200 in 0.6% bovine serum albumin (BSA)/PBS, and then a 1 h incubation in goat anti-rabbit-TRITC (Southern Biotech) antibody. Injected cells (containing mouse IgG) were identi®ed using goat anti-mouse-FITC (DAKO).
To quantify cell proliferation, dishes were refed 24 h postinjection with medium containing 10 mM BrdU and incubated for 24 h before ®xing for 15 min in 4% paraformaldehyde/ PBS. This was followed by`quenching' in glycine, permeabilization in 0.2% Triton X-100 for 30 min and blocking' with FCS. Cells were then incubated for 30 min with goat anti-rabbit-TRITC (Southern Biotech) in 0.6% BSA/PBS to detect the rabbit IgG`marker' co-injected with 3G5 (or control) mouse antibody. BrdU incorporation was then detected by incubation for 1 h at 378C in 25 mU/ml DNAse 1 (Promega) followed by directly-labelled mouse antiBrdU-FITC (1 : 20) (Boehringer).
